Trimeris names new CEO
Former GlaxoSmithKline Senior VP-Global Commercial Strategy Steven Skolsky takes top leadership slot at Trimeris effective Sept. 9. Skolsky succeeds company founder Dani Bolognesi, PhD, who is staying on as chief scientific officer. Skolsky's appointment fills a need for senior leadership following the departure of Trimeris' President Nixon Ellis, PhD, in June. At GSK, Skolsky's most recent post is being filled by Richard Wallace, who moved up from VP-global therapeutic area strategy for psychiatry...
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.